comparemela.com
Home
Live Updates
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for… : comparemela.com
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for…
JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. ENTX ("Entera" or the "Company"), a leader in the development of orally delivered peptides,…
Related Keywords
United States ,
Jerusalem ,
Israel General ,
Israel ,
American ,
,
Mineral Research ,
Pamerican Society For Bone ,
Drug Administration ,
Entera Bio Ltd ,
American Society ,
News ,
Ggregator ,
Reaking News ,
Uration ,
Media ,
comparemela.com © 2020. All Rights Reserved.